{"id":"vehicle-to-oxymetazoline-hcl-cream","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site erythema"},{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Rebound erythema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxymetazoline works by stimulating alpha-1 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction of small blood vessels in the dermis. This reduces blood flow to the affected areas and decreases the appearance of facial erythema and redness. The effect is topical and localized to the area of application.","oneSentence":"Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:26.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent facial erythema associated with rosacea"}]},"trialDetails":[{"nctId":"NCT05148689","phase":"PHASE1","title":"A Study Comparing Oxymetazoline 1% Cream to RHOFADE","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2018-02-23","conditions":"Bioequivalence","enrollment":82},{"nctId":"NCT03954444","phase":"PHASE3","title":"A Clinical Endpoint Bioequivalence Study of \"Oxymetazoline Hydrochloride Cream\"","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2019-04-15","conditions":"Rosacea","enrollment":1105},{"nctId":"NCT02132117","phase":"PHASE3","title":"Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06","conditions":"Erythema, Rosacea","enrollment":445}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle to Oxymetazoline HCL Cream","genericName":"Vehicle to Oxymetazoline HCL Cream","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxymetazoline HCL is a selective alpha-1 adrenergic agonist that constricts blood vessels in the skin to reduce facial redness and erythema. Used for Persistent facial erythema associated with rosacea.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}